logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Class
    3. Serotonin-3 Receptor Antagonist

    Serotonin-3 Receptor Antagonist class drugs

    FiltersReset Filters
    7 results

    • akynzeo

      (Netupitant and Palonosetron)
      Helsinn Therapeutics (U.S.), Inc.
      Usage: AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing initial and repeat courses of highly emetogenic cancer chemotherapy, used in combination with dexamethasone. It consists of palonosetron and netupitant (or fosnetupitant in injectable form).

    • ondansetron

      (Ondansetron)
      ACTAVIS PHARMA, INC.
      Usage: Ondansetron tablets are indicated for preventing nausea and vomiting from highly and moderately emetogenic cancer chemotherapy, radiotherapy (including total body irradiation and abdominal treatments), and postoperative settings.

    • ondansetron

      (Ondansetron)
      Natco Pharma USA LLC
      Usage: Ondansetron tablets are indicated for preventing nausea and vomiting from highly and moderately emetogenic cancer chemotherapy, specific radiation treatments, and postoperative nausea or vomiting.

    • ondansetron hydrochloride

      (Ondansetron Hydrochloride)
      Chartwell RX, LLC.
      Usage: Ondansetron oral solution is indicated for preventing nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, specific radiotherapy approaches, and postoperative periods.

    • palonosetron

      (Palonosetron)
      NorthStar Rx LLC
      Usage: Palonosetron hydrochloride injection is indicated for preventing acute and delayed nausea and vomiting related to moderately and highly emetogenic cancer chemotherapy in adults and pediatric patients. It also prevents postoperative nausea and vomiting for up to 24 hours after surgery, but routine prophylaxis is not recommended when the risk is low.

    • palonosetron hydrochloride

      (Palonosetron Hydrochloride)
      Eugia US LLC
      Usage: Palonosetron hydrochloride injection is indicated for preventing acute and delayed nausea and vomiting in adults undergoing moderately and highly emetogenic chemotherapy, as well as for preventing postoperative nausea and vomiting. It is also indicated for pediatric patients aged 1 month to under 17 years for chemotherapy-related nausea.

    • sustol

      (granisetron)
      Heron Therapeutics, Inc.
      Usage: SUSTOL is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) regimens, in combination with other antiemetics.